Cardiff Oncology Inc Stock News

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE)...

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025.

Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivotal catalyst, with positive results potentially unlocking blockbuster sales and significant share price appreciation. Key risks include clinical trial execution, capital needs, and heavy reliance on...

Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in Phase 2 trials for RAS-mutated metastatic colorectal and triple-negative breast cancers. Despite competition and clinical-stage risks, onvansertib's unique PLK1 inhibition mechanism offers breakthrou...

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in October 2025.

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor conferences in September 2025. Details of the events can be found below.

Cardiff Oncology (CRDF) Q2 Loss Down 19%

Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, reflecting typical regression to the mean and leaving some questions unanswered until the next update in Q1 2026. CRDF's cash position is stable for now, but a future financing need is likely as the co...